Abionyx Pharma reported consolidated revenue of €1.9 million for the first half of 2026, down from €2.1 million in the same period last year. The biopharmaceutical company’s cash position strengthened significantly to €26.9 million as of June 30, 2026.

The decline in top-line figures reflects the ongoing development phase of Abionyx’s core sepsis therapies. The company generated no revenue from its primary biotech activities during the quarter, continuing to provide its bioproduct free of charge under Compassionate Use Authorization (AAC) applications.

Revenue Composition

All consolidated revenue for the period originated from Abionyx’s subsidiary, IRIS Pharma. This unit operates as a contract research organization (CRO) specializing in ophthalmology. Management anticipates that IRIS Pharma’s revenue for fiscal year 2026 will remain broadly stable compared to fiscal year 2025.

Balance Sheet Position

The group’s cash and cash equivalents stood at €26.9 million at the end of the period, a substantial increase from €3.4 million recorded in Q2 2025. This improvement followed a financing transaction announced on June 18, 2026.

This cash balance is reported prior to the receipt of Research Tax Credits and grants under the France 2030 plan. The company states that its financial visibility extends through the end of 2028.

What the Numbers Show

The data highlights a clear bifurcation in Abionyx’s financial structure. While the core therapeutic pipeline generates zero commercial revenue due to compassionate use provisions, the CRO subsidiary provides a stable, albeit declining, income stream. The massive jump in cash reserves—from €3.4 million to €26.9 million—indicates that the recent financing transaction was the primary driver of liquidity improvement, rather than operational cash flow generation.

Note: The H1 2026 financial statements have not yet been approved by the Board of Directors and are undergoing limited review by statutory auditors.

ABIONYX Pharma disclosed its total voting rights and share capital data as of June 30, 2026, in compliance with Article L233-8-II of the French Commercial Code and Article 223-16 of the General Regulations of the AMF. The company reported 42,568,071 shares outstanding on Euronext Paris, Compartment C, under the ISIN code FR0012616852.

The filing details the total voting rights, distinguishing between gross and net figures. The total number of gross voting rights, used as the basis for calculating threshold crossings, stood at 52,292,148. This figure includes all shares to which voting rights are attached, encompassing those for which voting rights have been suspended, in accordance with Article 223-11 of the AMF General Regulations.

The total number of net voting rights, which excludes shares with suspended voting rights, was reported at 52,017,701. This metric is released to ensure proper public information, aligning with the AMF recommendation dated July 17, 2007.

Share Capital and Voting Rights

The following table summarizes the company's share capital and voting rights as of the specified date:

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases with no effective or existing treatment, including rare conditions. The company leverages expertise in lipid science and a differentiated apoA-I-based technology platform to expedite therapeutic development. ABIONYX Pharma is committed to improving treatment outcomes in sepsis and critical care.